Should I Buy EOLS? EOLS 2026 Analysis

Should You Buy Evolus Inc (EOLS) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

4.500

1 Day change

2.04%

52 Week Range

17.120

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient investor: the primary trend remains bearish (SMA_200 > SMA_20 > SMA_5) and price is still below key pivot resistance (4.799).
While near-term bounce odds exist (RSI_6 ~33.8, MACD histogram positive and expanding), there is no Intellectia signal confirming a high-conviction entry today.
Strong negative behavioral flag: insiders are selling and selling accelerated (+113% last month), which outweighs the moderately bullish options skew.
Practical takeaway: avoid initiating a new long position today; the risk of further downside through support (4.562 then 4.416) is still meaningful.

Intellectia Proprietary Trading Signals

AI Stock Picker: No signal on given stock today.
SwingMax: No signal on given stock recently.

Technical Analysis

Trend: Bearish structure with moving averages stacked down (SMA_200 > SMA_20 > SMA_5), suggesting rallies are likely to face selling pressure.
Momentum: MACD histogram 0.0171 is above zero and expanding, indicating a potential early-stage rebound attempt.
RSI: RSI_6 at 33.75 is weak/near-oversold territory (not a strong buy signal by itself, but supports the possibility of a short-term bounce).
Key levels:
- Support: S1 4.562 (very close), then S2 4.416.
- Resistance: Pivot 4.799, then R1 5.036.
Near-term path: A bounce is plausible if 4.562 holds, but the stock still needs to reclaim 4.799–5.036 to meaningfully improve the technical picture.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Positioning/Sentiment: Put-call ratios are low (OI PCR 0.31; Volume PCR 0.25), indicating bullish skew/speculative call interest vs puts.
Activity: Today’s option volume (106) is elevated vs its 30-day average (17.26x), suggesting heightened short-term attention.
Volatility: 30D IV ~57.23 vs HV ~61.17; IV percentile ~45.42 (mid-range). Not “extreme fear,” more neutral-to-elevated volatility.
Interpretation: Options lean bullish for a bounce, but this is not confirmed by trend-following technicals and is contradicted by insider selling.

Technical Summary

Sell

Buy

Positive Catalysts

holds.

Neutral/Negative Catalysts

- Primary trend remains bearish (downward MA stack), meaning rallies can fail quickly.
- Insiders are selling, and selling increased ~113% over the last month (not supportive of a “buy now” call).
- Fundamental profitability pressure: net losses widened YoY and gross margin declined.
- Sector/backdrop: analyst commentary references steep declines across the aesthetic injectables category in 2025, implying a tougher demand environment.
- No news/catalysts in the last week to justify an immediate re-rating.

Financial Performance

Latest quarter: 2025/Q3.
Revenue: $68.97M, +12.9% YoY (healthy top-line growth).
Profitability: Net income -$15.74M (worse by ~17.9% YoY) and EPS -$0.24 (down ~20% YoY), showing losses deepened despite revenue growth.
Margins: Gross margin 64.03%, down ~6.38% YoY, indicating cost/price pressure.
Read-through: Growth is present, but the quality of growth weakened (margin and losses deteriorated), which helps explain why the stock can stay technically weak.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent changes:
- 2026-01-22: BTIG cut price target to $13 from $18, reiterated Buy (reflecting reduced long-term assumptions after category weakness).
- 2025-11-06: Mizuho raised price target to $20 from $19, reiterated Outperform (citing strong Jeuveau performance and a post-earnings rally setup).
Wall Street pros (bull case): Jeuveau demand/prints can surprise positively; multiple firms keep bullish ratings with targets well above current price.
Wall Street cons (bear case): Targets are being rebased lower due to category slowdown; near-term execution/margin pressure remains a concern.
Influential/congress trading: No recent congress trading data available (no signal from politician activity in the provided dataset).

5 Analyst Rating

Wall Street analysts forecast EOLS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EOLS is 19.25 USD with a low forecast of 18 USD and a high forecast of 20 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

1 Hold

0 Sell

Strong Buy

Current: 4.410

Low

Averages

19.25

High

Current: 4.410

Low

Averages

19.25

High

Mizuho

Uy Ear

Outperform -> NULL

downgrade

$19 -> $15

AI Analysis

2026-02-04

New

Reason

Mizuho

Uy Ear

Price Target

$19 -> $15

AI Analysis

2026-02-04

New

downgrade

Outperform -> NULL

Reason

Mizuho analyst Uy Ear lowered the firm's price target on Evolus to $15 from $19 and keeps an Outperform rating on the shares. The firm updated the company's model post the lower than expected preannounced Q4.

BTIG

Buy

downgrade

$18 -> $13

2026-01-22

Reason

BTIG

Price Target

$18 -> $13

2026-01-22

downgrade

Buy

Reason

BTIG lowered the firm's price target on Evolus to $13 from $18 and keeps a Buy rating on the shares. The firm is updating its model to reflect updated 2026 and long-term guidance while noting that rebasing the market size and outlook was an appropriate step following steep declines across the aesthetic injectables category in 2025, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for EOLS

Unlock Now

EOLS Should I Buy

EOLS Should I Buy

Should You Buy Evolus Inc (EOLS) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch